GI 4000
Alternative Names: GI-4000Latest Information Update: 06 Sep 2024
At a glance
- Originator GlobeImmune
- Developer GlobeImmune; ImmunityBio
- Class Cancer vaccines
- Mechanism of Action Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Colorectal cancer; Pancreatic cancer; Triple negative breast cancer
- Suspended Non-small cell lung cancer; Solid tumours
Most Recent Events
- 01 Aug 2024 ImmunityBio terminates a QUILT-3.080 phase I/II trial in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (IV) prematurely (NCT03586869)
- 22 May 2024 NantKwest terminates a phase I/II QUILT3-070 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (NCT03387098)
- 16 Jan 2024 ImmunityBio terminates a Phase-I/II clinical trials in Triple negative Breast cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (SC) prematurely (NCT03387085)